ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Sclerosis
Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Muscle Spasticity

Multiple Sclerosis (MS) trials near Barcelona, CT, ESP:

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis (MAXIMS)

the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple...

Enrolling
Progressive Multiple Sclerosis
Drug: Placebo
Drug: Masitinib (4.5)

Phase 3

AB Science
AB Science

Barcelona, Spain and 36 other locations

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

Phase 3

Roche
Roche

Barcelona, Spain and 161 other locations

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...

Enrolling
Multiple Sclerosis
Drug: Placebo capsule
Drug: Fingolimod

Phase 3

Novartis
Novartis

Barcelona, Catalunya, Spain and 107 other locations

This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple...

Enrolling
Multiple Sclerosis, Relapsing-Remitting
Drug: Interferon beta type 1a
Drug: BIIB017 (peginterferon beta-1a)

Phase 3

Biogen
Biogen

Esplugues de Llobregat, Barcelona, Spain and 65 other locations

with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and \< 18 years over a dura...

Enrolling
Relapsing-Remitting Multiple Sclerosis
Other: Ocrelizumab Placebo
Drug: Ocrelizumab

Phase 3

Roche
Roche

Barcelona, Spain and 118 other locations

study will compare ofatumumab vs. European approved platform first line self-administered disease modifying therapy (DMT) in newly diagnosed MS...

Enrolling
Multiple Sclerosis
Drug: Ofatumumab
Drug: First line DMT

Phase 3

Novartis
Novartis

Barcelona, Spain and 49 other locations

Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or...

Active, not recruiting
Relapsing Multiple Sclerosis
Biological: Ofatumumab

Phase 3

Novartis
Novartis

Barcelona, Cataluna, Spain and 122 other locations

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Phase 3

Novartis
Novartis

Barcelona, Spain and 208 other locations

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Phase 3

Novartis
Novartis

Barcelona, Catalunya, Spain and 225 other locations

The primary objective of Part 2 is to evaluate the long-term safety of BG00012 in subjects who completed Week 96 in Part 1 of Study 109MS306...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis
Drug: dimethyl fumarate
Drug: Interferon β-1a

Phase 3

Biogen
Biogen

Barcelona, Spain and 61 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems